Advertisement

Pharmacological Management of ADHD

  • Joseph Sadek
Chapter

Abstract

Medications should only be used when symptoms are pervasive across settings (e.g., school and home), and are causing significant impairment in academic, social or behavioral function, and after careful consideration of non-pharmacological approaches.

Keywords

Attention Deficit Hyperactivity Disorder Immediate Release Product Monograph Extended Release Form Mixed Amphetamine Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

General References and Related Reading

  1. Adler LA, Spencer TJ, Milton DR et al (2005) Long term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit hyperactivity disorder: an interim analysis. J Clin Psychiatry 66(3):294–299PubMedCrossRefGoogle Scholar
  2. Adler LA, Spencer TJ, Faraone SV et al (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67(3):415–420Google Scholar
  3. Baranski JV, Pigeau R, Dinich P et al (2004) Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 19(5):323–332PubMedCrossRefGoogle Scholar
  4. Biederman J, Balderssarini RJ, Wright V et al (1989) A double-bind placebo controlled study of Desipramine in the treatment of attention deficit disorder: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784PubMedCrossRefGoogle Scholar
  5. Biederman J, Melmed RD, Patel A et al (2008) A randomized, double-blind, placebo-controlled study of Guanfacine extended release in children and adolescents with attention-deficit hyperactivity disorder. Pediatrics 121(1):e73–e84PubMedCrossRefGoogle Scholar
  6. CADDRA (2011) Canadian ADHD Practice Guidelines [online] In: Umesh J, Hechtman L et al., editors. www.caddra.ca
  7. Childress AC, Berry SA (2012) Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs 72(3):309–325PubMedCrossRefGoogle Scholar
  8. Coghil D (2011) Pragmatic measures in paediatric psychopharmacology – are we getting it right? Eur Neuropsychopharmacol 21(8):571–583CrossRefGoogle Scholar
  9. Conners CK, Casat CD, Gualtieri CT et al (1996) Burpropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321PubMedCrossRefGoogle Scholar
  10. Connor DF (2005) Psychostimulants in attention deficit hyperactivity disorder. In: Gozal D, Molfese DL, editors. Attention deficit hyperactivity disorder: from genes to patients. New Jersey: Humana Press, pp. 487–527Google Scholar
  11. Connor DF, Findling RL, Kollins SH et al (2010) Effects of Guanfacine extended release, a nonscheduled alpha 1A-adrenoceptor agonist, on oppositional symptoms in children aged 6 to 12 years with a diagnosis of attention-deficit hyperactivity disorder and the presence of oppositional symptom. CNS Drugs 24(9):755–768PubMedGoogle Scholar
  12. Daughton JM, Kratochvil CJ (2009) Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adoloesc Psychiatry 48(3):240–248CrossRefGoogle Scholar
  13. Davidson MA (2008) ADHD in adults: a review of the literature. J Atten Disord 11(6):628–641PubMedCrossRefGoogle Scholar
  14. Dopheide JA, Pliszka SR (2009) Attention-deficit hyperactivity disorder: an update. Pharmacotherapy 29(6):656–679PubMedCrossRefGoogle Scholar
  15. Findling RL (2008) Evolution of the treatment of attention-deficit hyperactivity disorder in children: a review. Clin Ther 30(5):942–957PubMedCrossRefGoogle Scholar
  16. Garnock-Jones KP, Keating GM (2010) Spotlight on Atomoxetine in attention-deficit hyperactivity disorder in children and adolsecents. CNS Drugs 24(1):85–88PubMedCrossRefGoogle Scholar
  17. Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22(3):231–237CrossRefGoogle Scholar
  18. Greenhill LL, Biederman J, Boellner SW (2002) A randomized, double-blind, placebo-controlled study of Modafinil film-coated tablets in children and adolescents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(5):503–511CrossRefGoogle Scholar
  19. Greenhill L, Kollins S et al (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45(11):1284–93Google Scholar
  20. Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristic of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254PubMedCrossRefGoogle Scholar
  21. Huang YS, Tsai MH (2001) Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. CNS Drugs 25(7):539–554, Erratum in: CNS Drugs. 2011 Nov. 1, 25(11): 932, Dosage error in article textCrossRefGoogle Scholar
  22. Humphreys C, Carcia-Bournissen F, Ito S, Koren G (2007) Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician 53(7):1153–1155PubMedGoogle Scholar
  23. Kaplan G, Newcorn JH (2011) Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin N Am 58(1):99–120, xiCrossRefGoogle Scholar
  24. Kolar D (2008) Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 4(2):389–403PubMedGoogle Scholar
  25. Kratochvil DJ, Newcorn JH, Arnold LE (2005) Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44(9):915–924PubMedCrossRefGoogle Scholar
  26. Kratochvil CJ, Wilens TE, Grennhill LL et al (2006) Effects of long term Atomoxetine treatment for young children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(8):919–927PubMedCrossRefGoogle Scholar
  27. Levin FR, Evans SM, McDowell DM et al (2002) Bupropion treatment for cocaine abuse and adult attention-deficit hyperactivity disorder. J Addict Disord 21(2):1–16CrossRefGoogle Scholar
  28. Lin JS, Gervansoni D, Hou Y et al (2000) Effects of amphetamine and Modafinil on the sleep/wake cycle during experimental hypersomnia induces by sleep deprivation in the cat. J Sleep Res 9(1):89–96PubMedCrossRefGoogle Scholar
  29. Meijer WM, Faber A, van den Ban E, Tobi H (2009) Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci 31(5):509–516, Epub 2009 Jun 27PubMedCrossRefGoogle Scholar
  30. Michelson D, Faries DE, Wernicke J et al (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit hyperactivity disorder: a randomized, placebo controlled, dose–response study. Pediatrics 108(5):E83PubMedCrossRefGoogle Scholar
  31. Michelson D, Kratochvil CJ, Heligenstein JH et al (2002) Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41(7):776–784PubMedCrossRefGoogle Scholar
  32. Michelson D, Adler L, Spencer T et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53(2):112–120PubMedCrossRefGoogle Scholar
  33. Murray DW (2010) Treatment of preschoolers with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 12(5):374–381PubMedCrossRefGoogle Scholar
  34. Pliszka SR et al (2006) Texas Consensus Conference Panel on Pharmacotherapy of childhood attention deficit hyperactivity disorder. The Texas Childrens’ Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(6):642–657PubMedCrossRefGoogle Scholar
  35. Pliszka S (2007) AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894–921Google Scholar
  36. Prince JB (2006) Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, Atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 15(1):13–50PubMedCrossRefGoogle Scholar
  37. Pringsheim T, Steeves T (2011) Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev (4):CD007900Google Scholar
  38. Rostain AL (2008) Attention-deficit hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad Med 120(3):27–38PubMedCrossRefGoogle Scholar
  39. Safety and side effect information in children, teens and adults (2011). http://www.strattera.com
  40. Salle FR, McGough J, Wigel T et al (2009) Guanfacine extended release in children and adolescents with attention-deficit hyperactivity disorder: a placbo-controlled trial. J Am Acad Child Adolesc Psychiatry 48(2):155–165CrossRefGoogle Scholar
  41. Sallee FR, Eaton K (2010) Guanfacine extended-release for attention-deficit hyperactivity disorder (ADHD). Expert Opin Pharmacother 11(15):2549–2556PubMedCrossRefGoogle Scholar
  42. Santosh PJ, Sattar S, Canagaratnam M (2011) Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 25(9):737–763PubMedCrossRefGoogle Scholar
  43. Schachar R, Ickowicz A, Crosbie J et al (2008) Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 18(1):11–24PubMedCrossRefGoogle Scholar
  44. Slatkoff J, Greenfiled B (2006) Pharmacological treatment of attention-deficit hyperactivity disorder in adults. Expert Opin Investig Drugs 15(6):649–667PubMedCrossRefGoogle Scholar
  45. Solkhah R, Wilens TE, Daly J et al (2005) Burpropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 15(5):777–786CrossRefGoogle Scholar
  46. Spencer TJ, Greenbaum M, Ginsger LD, Murphy WR (2009) Safety and effectiveness of co-administration of Guanfacine extended release and psychostimulants in children and adolescents with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 19(5):501–510PubMedCrossRefGoogle Scholar
  47. Swanson JM, Greenhill LL, Lopez FA et al (2006) Modafinil film-coated tablets in children and adolescents with attention – deficit hyperactivity disorder: results of a randomized, double-blind, placebo-controlled fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67(1):137–147PubMedCrossRefGoogle Scholar
  48. Turner DC, Clark L, Dowson J et al (2004) Modafinil improves cognition and response inhibition in adult attention-deficit hyperactivity disorder. Biol Psychiatry 55(10):1031–1040PubMedCrossRefGoogle Scholar
  49. Vitiello B (2008) Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 17(2):459–474, xiPubMedCrossRefGoogle Scholar
  50. Wang Y, Zheng Y, Du Y et al (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 41(3):222–30Google Scholar
  51. Wernicke JF, Kratochvil CJ (2002) Safety profile of Atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63(12):50–55PubMedGoogle Scholar
  52. Wigal SB (2009) Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 23(1):21–31PubMedCrossRefGoogle Scholar
  53. Wigal SB, Cahe S, Patel A, Steinberg-Epstein R (2010) Advances in the treatment of attention-deficit hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol 17(4):230–236PubMedCrossRefGoogle Scholar
  54. Wilens TE (2006) Mechanism of action of agents used in attention-deficit hyperactivity disorder. J Clin Psychiatry 67(8):32–38PubMedGoogle Scholar
  55. Wilens TE, Spencer TJ (2010) Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 122(5):97–109PubMedCrossRefGoogle Scholar
  56. Wilens TE, Spencer TJ, Biederman J et al (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158(2):282–288PubMedCrossRefGoogle Scholar
  57. Wilens TE, Spencer TJ, Biederman J (2002) Attention deficit/hyperactivity disorder across the life span. Ann Rev Med 53:113–131Google Scholar
  58. Wilens TE, Newcorn JJ, Kratochovil CJ et al (2006) Long term Atomoxetine treatment in adolescents with attention-deficit hyperactivity disorder. J Pediatr 146(1):112–119CrossRefGoogle Scholar
  59. Wolraich ML et al (2005) Attention-deficit hyperactivity disorder among adolescents: a review of the diagnosis, treatment and clinical implications. Pediatrics 115(6):1734–1746PubMedCrossRefGoogle Scholar

ADHD Guidelines Available on the Internet

  1. American Psychological Association. http://www.apa.org/topics/adhd/index.aspx
  2. Australian ADHD Draft Guidelines. http://www.nhmrc.gov.au/guidelines/publications/ch54
  3. Canadian ADHD Guidelines. http://www.caddra.ca/cms4/
  4. National Institute for Health and Clinical Excellence (NICE). http://publications.nice.org.uk/attention-deficit-hyperactivity-disorder-cg72

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Joseph Sadek
    • 1
  1. 1.Department of PsychiatryDalhousie UniversityHalifaxCanada

Personalised recommendations